Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may have made regarding its business operations and prospects.
The investigation focuses on Morphic's representations regarding its Phase 2a trial for MORF-057 proposed to be used in the treatment of severely active ulcerative colitis. In September 2023, Morphic announced that endoscopic improvement was achieved in 25.7% of patients in the trial at week 12, which was a lower rate than on other ulcerative colitis trials from competitors. These other trials typically found that the rate of endoscopic improvement was higher than the rate of clinical remission.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Ademi LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.com
White Mountains Insurance Group, Ltd. announced today that MediaAlpha, Inc. ("MediaAlpha") priced an underwritten secondary public offering of 6,600,000 shares (not including 990,000 shares subject to the underwriters' option to purchase additional...
ICC Holdings, Inc. (the Company), parent company of Illinois Casualty Company, a regional, multi-line property and casualty insurance company focusing exclusively on the food and beverage industry, today reported unaudited results for the three...
Telefônica Brasil - , announces its results for 1Q24:
1Q24 Results: Telefônica Brasil S.A.
Strong operating performance leading to above-inflation growth in revenues, EBITDA and net income
R$ million
1Q24
1Q23
% Y-o-Y
Net Operating Revenue
13,546...
Information Services Corporation ("ISC" or the "Company") today reported on the Company's financial results for the first quarter ended March 31, 2024. Capitalized terms that are used but not defined in this news release have the meaning ascribed...
Fresh off the revamped formula release of their patented creatine infused ready to drink recovery beverage, FITAID delivers a unique product drop strategy, putting customers in control of their permanent flavor collection. With the record...